U.S FDA issues 5 observations to Aurobindo Pharma arm’s facility in AP  

The U.S. Food and Drug Administration (U.S. FDA) has issued five observations to Aurobindo Pharma stepdown subsidiary Eugia Steriles’ facility in Andhra Pradesh.

The observations were issued after a pre-approval inspection (PAI) of the facility in Parawada mandal, Anakapalli district, from February 10-18. The observations are procedural in nature and will be responded to within the stipulated time, Aurobindo Pharma said in a filing on Tuesday.

Eugia Steriles is a 100% subsidiary of Eugia Pharma Specialities and a stepdown subsidiary of the company.